Educating Stakeholders and Preparing for Bispecific Antibodies Across Lymphoma Indications

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

EP: 8.Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

EP: 9.Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

EP: 10.Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma

EP: 11.Optimizing Epcoritamab Dosing and Treatment Considerations in Second-Line Follicular Lymphoma

EP: 12.Best Practices for Managing Cytokine Release Syndrome and ICANS with Bispecific Antibodies in Follicular Lymphoma

Now Viewing

EP: 13.Educating Stakeholders and Preparing for Bispecific Antibodies Across Lymphoma Indications

Effective integration of bispecific antibodies in follicular lymphoma relies on comprehensive education for both patients and healthcare providers. Patients benefit from clear explanations about therapy mechanisms, administration schedules, potential adverse events, and strategies for self-monitoring, empowering them to engage actively in their care. Concurrently, educating healthcare providers—including physicians, nurses, and pharmacists—ensures familiarity with dosing protocols, toxicity management, and workflow coordination. As bispecific antibodies expand into early-line treatment for diffuse large B-cell lymphoma (DLBCL), operational considerations such as infusion scheduling, monitoring for cytokine release syndrome and neurotoxicity, and resource allocation become increasingly critical. Multidisciplinary collaboration and proactive planning are essential to manage these challenges effectively. By fostering education and preparedness across all stakeholders, healthcare teams can optimize safety, efficacy, and patient experience, setting the stage for successful adoption of bispecific therapies across lymphoma subtypes.